Business Context and Reporting Period
This Form 8-K is a current report filed by NantKwest, Inc. (not Immunitybio, Inc.) on June 6, 2019. The filing covers events occurring at the Company's 2019 Annual Meeting of Stockholders held on the same date. NantKwest is a biopharmaceutical company incorporated in Delaware, with its common stock trading on the Nasdaq Global Select Market under the symbol "NK".
Key Financial Metrics
This filing is a current report regarding corporate governance and equity matters; it does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial performance metrics.
Material Changes and Corporate Actions
- Equity Plan Amendment: Stockholders approved the amendment and restatement of the 2015 Equity Incentive Plan, increasing the number of reserved common stock shares by 3,000,000.
- Board Expansion: The Board of Directors increased the number of directors from six to seven.
- Director Appointment: Cheryl L. Cohen was appointed to the Board effective immediately, with a term expiring at the 2020 annual meeting. She will serve on the Audit Committee.
- Director Compensation: Ms. Cohen received a restricted stock unit (RSU) award valued at $325,000, vesting annually over three years. She is also eligible for annual RSU grants valued at $100,000 and cash compensation totaling $60,000 annually ($50,000 base + $10,000 for Audit Committee service).
Guidance, Outlook, and Voting Results
The filing does not provide financial guidance, outlook, or management commentary on business risks. It details the results of the 2019 Annual Meeting where 93.91% of outstanding shares were represented:
- Election of Directors: All six nominees (Patrick Soon-Shiong, Barry J. Simon, Steve Gorlin, Michael D. Blaszyk, Frederick W. Driscoll, and John C. Thomas, Jr.) were elected with significant majority support.
- Equity Plan Approval: The amendment to increase share reserves was approved with 73,430,363 votes for and 4,274,242 votes against.
- Auditor Ratification: The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019, was ratified with 91,572,889 votes for.
Investor Verification Checklist
- Verify the exact number of shares reserved under the Amended and Restated 2015 Equity Incentive Plan by reviewing the full text of Exhibit 10.1.
- Confirm the vesting schedule and specific terms of the $325,000 RSU award granted to Cheryl L. Cohen.
- Review the 2019 Proxy Statement (filed April 26, 2019) for the complete description of the equity plan amendment.
- Check subsequent filings for any changes to the Board composition or compensation policies following this appointment.